Sneak Peek: Targeting mRNA with Small Molecules: David Weitz, Syrna Therapeutics

What if we could stop disease-causing proteins before they're even made—using small molecules to target their mRNA?David Weitz, CEO of Syrna Therapeutics, is pioneering exactly that: 3D structure-guided drug discovery for mRNA, coupled with covalent translation inhibitors that silence proteins at the source.🎙️ Full episode drops 7 January 2026In the complete interview, we dive into:• Why mRNA is an untapped drug target• 3D structure-guided discovery and covalent inhibitors• Lead programs in immunology and neurodegeneration• Building Syrna and coming out of stealthSubscribe so you don't miss it.#SneakPeek #mRNA #DrugDiscovery #Biotech